beigene.com (ONC): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
BeiGene Ltd margins are suffering from strict government regulation in China, however, on GURU.Markets, the EV/EBITDA trend for the business, where the parameter is 29.43, confirms the company's resilience. Global partnerships and M&A deals that bring drugs to market ensure this stability. Leadership in creating targeted molecules makes cancer therapy maximally effective and less toxic.
ONC (beigene.com): analytical breakdowns and indicator data
- stock price and consensus target price:
- stock exchange capitalization data:
- book value of equity indicators:
- debt and solvency information:
- financial results and valuation multiples details:
ONC - Company Profit|Projected Future Earnings BeiGene Ltd|ONC - Market Cap to Earnings|Projected Price to Earnings BeiGene Ltd|ONC - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BeiGene Oncology|ONC - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months BeiGene|ONC - Earnings per share for the last four quarters|Quarterly EPS earnings growth beigene.com|ONC - Earnings per share growth this year|Net earnings per share growth forecast for next year BeiGene Ltd
Comprehensive company analysis:BeiGene Corp ONC
Investors evaluate BeiGene Ltd (ONC) through the lens of capital-intensive biotechnological development and debt load. This metric compares the total enterprise value with its operating profit before depreciation and amortization, determining the real value of assets relative to cash flow. By analyzing the historical EV/EBITDA trend of BeiGene Ltd (ONC), one can identify periods of stock undervaluation. Management's competence in drug commercialization minimizes credit risks, ensuring the fundamental stability of the business.
Main competitors
Halozyme Inc. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Revolution Medicines Corp RVMD|AAPG - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CGON (cgoncology.com)|URGN: EV/EBITDA Multiple|Company Value to EBITDA Bicara Therapeutics Inc (BCAX)|PSNL (Personalis Corp) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ERAS|EV/EBITDA Multiple DCTH|YMAB - Company Value to EBITDA|EV/EBITDA Multiple AURA (Aura Biosciences)|Total Company Value to Operating Income Before Depreciation Ratio Candel Therapeutics Inc. (CADL)|Accuray Inc. - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple SELLAS Life Sciences (SLS)|ACTU: EV/EBITDA Multiple|Company Value to EBITDA citiusonc.com (CTOR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TuHURA Biosciences Inc.|Enterprise Value to Operating Income Before Depreciation TARA (Protara Therapeutics Inc)|EV/EBITDA Multiple FATE|WHWK - Company Value to EBITDA|TScan Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CSBR|XBIT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CVM: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OSTX (OS Therapies Inc) - Enterprise Value to EBITDA Ratio|RADX: Enterprise Value to Operating Income Before Depreciation Ratio|ARTV (Artiva Biotherapeutics Inc.) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ANL (Adlai Nortye Limited)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Veru (VERU)|TPST - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xilio Therapeutics XLO|RENB: Enterprise Value to Operating Income Before Depreciation|Mural Bio - EV/EBITDA Multiple|Kairos Pharma Ltd (KAPA) - Enterprise Value to EBITDA Ratio|OKUR: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio CytoMed Therapeutics Limited|CRIS (Curis Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Apollomics Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tharimmune, Inc. (THAR)|advanbiomed.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple GNPX (Genprex)|CLDI - Enterprise Value to EBITDA Ratio|Sunshine Biopharma - EV/EBITDA Multiple|Company Value to EBITDA Xenetic Biosciences|Salarius Pharmaceuticals (SLRX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|purple-biotech.com - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio AONC|BGNE: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple CKPT|Enterprise Value to EBITDA Ratio Elevation Oncology Inc. ELEV|iCAD - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Ikena Oncology Inc. IKNA|NTBL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation VIRX (Viracta Therapeutics)|MOR: EV/EBITDA Multiple|Company Value to EBITDA NAYA Biosciences Corp (NAYA)|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
